Stock Events

Stock Events

Genmab

kr1,762

229

+kr26+1.5% Wednesday 15:09

Statistics

Day High

1,775

Day Low

1,746

52W High

2,251

52W Low

1,270

Volume

3,876,283

Avg. Volume

-

Mkt Cap

0

P/E Ratio

17.27

Dividend Yield

-

Dividend

-

Upcoming

Earnings

7MayExpected

Q3 2024

Q4 2024

Q1 2025

Q2 2025

Q3 2025

Q4 2025

Next

3.13

22.15

41.17

60.19

Expected EPS

9.90411701488

Actual EPS

N/A

Financials

25.89%Profit Margin

Profitable

2020

2021

2022

2023

2024

2025

47.7BRevenue

12.35BNet Income

Analyst Ratings

191.82Average Price Target

The highest estimate is 211.81.
From 6 ratings within the last 6 months. This is not an investment recommendation.

Buy

83%

Hold

17%

Sell

0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GMAB.CO. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Roche Holding AG is a major player in biotechnology, directly competing with Genmab in the development of monoclonal antibodies and cancer treatments.

Amgen Inc. competes in the biotech space, focusing on innovative therapeutics, including those for cancer, which overlaps with Genmab's focus areas.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is known for its work in monoclonal antibodies, directly competing with Genmab in several therapeutic areas.

Gilead Sciences

Gilead Sciences, Inc. operates in the biopharmaceutical field, competing with Genmab in the development of treatments for diseases such as cancer.

Bristol-Myers Squibb

Bristol-Myers Squibb Company competes with Genmab in the oncology sector, particularly in the development of innovative cancer treatments.

Merck & Co., Inc. is a global healthcare company that competes with Genmab in the development of cancer therapies and immunotherapy treatments.

Novartis AG competes with Genmab in the pharmaceutical and biotechnology sectors, particularly in the development of innovative medicines, including cancer treatments.

Pfizer Inc. is a global pharmaceutical company that competes with Genmab in the development of drugs for various diseases, including cancer.

AstraZeneca PLC is involved in the discovery and development of pharmaceuticals for several diseases, including cancer, making it a competitor to Genmab.

Johnson & Johnson

Johnson & Johnson operates in the pharmaceutical and biotechnology sectors, competing with Genmab in the development of innovative treatments for diseases, including cancer.

About

There is no Profile data available for GE9.SG.

Show more...

CEO

Dr. Jan G.J. van de Winkel Ph.D.

Employees

2973

Country

Denmark

ISIN

DK0010272202

Listings

0 Comments

Share your thoughts

FAQ

What is Genmab stock price today?▼

The current price of GMAB.CO is kr1,762 DKK — it has increased by +1.5% in the past 24 hours. Watch Genmab stock price performance more closely on the chart.

What is Genmab stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Genmab stocks are traded under the ticker GMAB.CO.

Is Genmab stock price growing?▼

GMAB.CO stock has risen by +4.26% compared to the previous week, the month change is a +0.6% rise, over the last year Genmab has showed a +29.13% increase.

What is Genmab revenue for the last year?▼

Genmab revenue for the last year amounts to 47.7B DKK.

What is Genmab net income for the last year?▼

GMAB.CO net income for the last year is 12.35B DKK.

How many employees does Genmab have?▼

As of May 07, 2026, the company has 2,973 employees.

In which sector is Genmab located?▼

Genmab operates in the Health & Wellness sector.

When did Genmab complete a stock split?▼

The last stock split for Genmab was on May 01, 2018 with a ratio of 5:1.

Where is Genmab headquartered?▼

Genmab is headquartered in Copenhagen, Denmark.